These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy. Sui H; Shi C; Yan Z; Li H Drug Des Devel Ther; 2015; 9():3183-90. PubMed ID: 26124641 [TBL] [Abstract][Full Text] [Related]
24. Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models. Santiago-O'Farrill JM; Weroha SJ; Hou X; Oberg AL; Heinzen EP; Maurer MJ; Pang L; Rask P; Amaravadi RK; Becker SE; Romero I; Rubio MJ; Matias-Guiu X; Santacana M; Llombart-Cussac A; Poveda A; Lu Z; Bast RC Cancer; 2020 Feb; 126(4):894-907. PubMed ID: 31714594 [TBL] [Abstract][Full Text] [Related]
25. BRCA Status Does Not Predict Synergism of a Carboplatin and Olaparib Combination in High-Grade Serous Ovarian Cancer Cell Lines. Shen YT; Evans JC; Zafarana G; Allen C; Piquette-Miller M Mol Pharm; 2018 Jul; 15(7):2742-2753. PubMed ID: 29750868 [TBL] [Abstract][Full Text] [Related]
26. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials. Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302 [TBL] [Abstract][Full Text] [Related]
27. Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition. Gabbasov R; Benrubi ID; O'Brien SW; Krais JJ; Johnson N; Litwin S; Connolly DC Cancer Biol Ther; 2019; 20(7):1035-1045. PubMed ID: 30929564 [TBL] [Abstract][Full Text] [Related]
28. MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib. Whicker ME; Lin ZP; Hanna R; Sartorelli AC; Ratner ES BMC Cancer; 2016 Jul; 16():550. PubMed ID: 27465688 [TBL] [Abstract][Full Text] [Related]
29. Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes. Wang D; Li C; Zhang Y; Wang M; Jiang N; Xiang L; Li T; Roberts TM; Zhao JJ; Cheng H; Liu P Gynecol Oncol; 2016 Sep; 142(3):548-56. PubMed ID: 27426307 [TBL] [Abstract][Full Text] [Related]
30. CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors. Lu X; He Y; Johnston RL; Nanayakarra D; Sankarasubramanian S; Lopez JA; Friedlander M; Kalimutho M; Hooper JD; Raninga PV; Khanna KK J Exp Clin Cancer Res; 2022 Dec; 41(1):355. PubMed ID: 36539830 [TBL] [Abstract][Full Text] [Related]
31. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations. Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458 [No Abstract] [Full Text] [Related]
32. Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer. Lin ZP; Zhu YL; Lo YC; Moscarelli J; Xiong A; Korayem Y; Huang PH; Giri S; LoRusso P; Ratner ES PLoS One; 2018; 13(11):e0207399. PubMed ID: 30444904 [TBL] [Abstract][Full Text] [Related]
33. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in Cardillo TM; Sharkey RM; Rossi DL; Arrojo R; Mostafa AA; Goldenberg DM Clin Cancer Res; 2017 Jul; 23(13):3405-3415. PubMed ID: 28069724 [No Abstract] [Full Text] [Related]
34. PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports. Collot T; Niogret J; Carnet M; Chevrier S; Humblin E; Favier L; Bengrine-Lefevre L; Desmoulins I; Arnould L; Boidot R Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33236159 [TBL] [Abstract][Full Text] [Related]
35. Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Li L; Karanika S; Yang G; Wang J; Park S; Broom BM; Manyam GC; Wu W; Luo Y; Basourakos S; Song JH; Gallick GE; Karantanos T; Korentzelos D; Azad AK; Kim J; Corn PG; Aparicio AM; Logothetis CJ; Troncoso P; Heffernan T; Toniatti C; Lee HS; Lee JS; Zuo X; Chang W; Yin J; Thompson TC Sci Signal; 2017 May; 10(480):. PubMed ID: 28536297 [TBL] [Abstract][Full Text] [Related]
36. Panobinostat enhances olaparib efficacy by modifying expression of homologous recombination repair and immune transcripts in ovarian cancer. Wilson AJ; Gupta VG; Liu Q; Yull F; Crispens MA; Khabele D Neoplasia; 2022 Feb; 24(2):63-75. PubMed ID: 34933276 [TBL] [Abstract][Full Text] [Related]
37. The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib. Wichmann C; Klotz DM; Zeiler HJ; Hilger RA; Grützmann K; Krüger A; Aust D; Wimberger P; Kuhlmann JD Gynecol Oncol; 2020 Dec; 159(3):850-859. PubMed ID: 32980128 [TBL] [Abstract][Full Text] [Related]
39. Cyclin D1 silencing impairs DNA double strand break repair, sensitizes BRCA1 wildtype ovarian cancer cells to olaparib. Zhong Q; Hu Z; Li Q; Yi T; Li J; Yang H Gynecol Oncol; 2019 Jan; 152(1):157-165. PubMed ID: 30414739 [TBL] [Abstract][Full Text] [Related]
40. Repurposing of mTOR Complex Inhibitors Attenuates MCL-1 and Sensitizes to PARP Inhibition. Mattoo AR; Joun A; Jessup JM Mol Cancer Res; 2019 Jan; 17(1):42-53. PubMed ID: 30201826 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]